iCo Therapeutics, Inc. announces agreement for in vivo testing of iCo- 019 on SARS-CoV-2
March 15, 2021, Vancouver, Canada - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) (“iCo” or
iCo Therapeutics Inc. Announces Warrant Exercises
March 11, 2021, Vancouver, Canada – iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) (“iCo” or
iCo Therapeutics Inc. Proposes to Re-Price Warrants
Vancouver, British Columbia--(Newsfile Corp. - January 11, 2021) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB:
iCo Therapeutics Announces Joint Development of iCo-019 with Skymount Medical
Vancouver, British Columbia--(Newsfile Corp. - December 31, 2020) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF)
iCo Therapeutics Announces Third Quarter 2020 Financial Results
Vancouver, British Columbia--(Newsfile Corp. - November 24, 2020) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF)